Verastem (VSTM) is now a commercial stage biotechnology pharmaceutical company with one approved drug, Copiktra. Verastem's stock price has fallen since it received its FDA approval. This reflects stock market conditions in Q4 2018, overenthusiasm leading up to the approval, and Verastem being relatively unknown to investors. It also fell a bit after Q4 results were released, though it has since seen some recovery.
I believe Copiktra is well-positioned to grow revenue substantially over the next few years. There are specific reasons to believe it will achieve physician acceptance in